#ryangarcia #devinhaney #gervontadavis "NOBODY'S cheating to beat no devin HANEY...TANK also thought ryan was on DRUGS!" THOUGHTS? #Boxing Trump calls Warren after she rips his policies in speech Why ...

Getting to sleep often takes longer than a beat. With 1 in 3 adults struggling to snooze, it’s no wonder many will try anything to get the recommended seven to nine hours or fall asleep fast. Binaural ...

Brace yourselves, Ozempic and Zepbound. Eli Lilly just released a jaw-dropping sneak peek from the final phases of testing for retatrutide (nicknamed "Reta"), a brand new GLP-1 weight loss drug that ...

TOLEDO, Ohio (WTVG) - The use and deaths related to fentanyl appear to be dropping, but there’s still plenty of it and far too many deaths. Now, a new push to stop it for good comes home. The Drug ...

New weight-loss drugs are working wonders, but they’re also out of many patients’ financial reach. Enrollees in Medicare, Medicaid and most employer insurance plans generally don’t cover them.

AstraZeneca Plc’s profit rose more than analysts anticipated last quarter, buoyed by demand for its blockbuster cancer and diabetes drugs. Earnings per share, excluding some items, climbed 14% to ...

These were just some of the chants that rang out through Downtown Chillicothe as students celebrated being drug-free during the 2025 rally and party in the park. Hundreds of students came from schools ...

Vertex Pharmaceuticals Inc. reported third-quarter sales that beat analysts’ expectations as the biotech company’s mainstay cystic fibrosis treatment saw revenue growth, even as new drugs’ ...

Nov 3 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis ...

The U.S. drug maker reported revenues of $7.77 billion, beating the consensus of $7.45 billion. Product sales decreased 2% to $7.3 billion, primarily driven by lower Veklury (remdesivir) and Cell ...

Bristol Myers Squibb Co. raised its revenue outlook for the year after newer medicines outperformed expectations, easing pressure on its portfolio of aging blockbusters. For the quarter, adjusted ...